Aurinia Pharmaceuticals Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
-11.5%projected annual EPS growth
Analyst Coverage
7analysts covering
FY Revenue (est.)
$329.1Mnext fiscal year
FY EPS (est.)
$0.94next fiscal year
Monitoring Framework
Key Performance Indicators
LUPKYNIS Net Product Sales Quarterly73.6MTarget: 305000000 to 315000000
Total Revenue Quarterly77.7MTarget: 315000000 to 325000000
Operating Cash Flow Quarterly32.6M
Watch Items
- Zetomipzomib Clinical DevelopmentTrigger: Initiation of Phase 2b/3 trials or clinical data readouts in autoimmune hepatitis (AIH) or lupus nephritis (LN)Action: Evaluate pipeline expansion progress and update risk-adjusted valuation models for the newly acquired Kezar assets.
- Aritinercept (AUR200) Clinical ProgressTrigger: Initiation of clinical study in a second autoimmune disease in H1 2026Action: Monitor clinical trial registry updates and corporate announcements regarding the specific indications targeted.
- Competitive Entry of GazyvaTrigger: Market share erosion or deceleration in LUPKYNIS new patient start forms (PSFs)Action: Assess quarterly commercial metrics and physician survey data to gauge competitive impact on LUPKYNIS.
Research as of 20 Jun 2026